Contract Research & Services
Clinical Trials

Clinical Trials News

View news from other Pharmaceutical sectors:
76-90 of 4306 results
Inovio, Parker Institute to jointly evaluate cancer immunotherapy combinations
Inovio Pharmaceuticals and the Parker Institute for Cancer Immunotherapy have signed a clinical collaboration agreement to assess novel combination regimens within the field of immuno-oncology.
Contract Research & Services > Clinical Trials > News
Axovant scraps dementia drug development after negative results
By PBR Staff Writer
Axovant Sciences said it will no longer develop intepirdine, its lead candidate for dementia, after failing to meet several goals in recent studies.
Contract Research & Services > Clinical Trials > News
Momenta, Mylan to start trial of biosimilar to eye drug Eylea
By PBR Staff Writer
Momenta Pharmaceuticals and Mylan have unveiled plans to commence pivotal clinical study of a biosimilar to Regeneron’s eye drug Eylea (aflibercept).
Contract Research & Services > Clinical Trials > News
Centrexion secures funding to begin trial of knee osteoarthritis pain drug
By PBR Staff Writer
Centrexion Therapeutics has secured $67m funding to launch phase 3 progam of CNTX-4975 therapy for the treatment of chronic pain due to knee osteoarthritis (OA).
Contract Research & Services > Clinical Trials > News
Atara gets FDA approval to start two phase 3 studies to assess tabelecleucel in patients with EBV+PTLD
Atara Biotherapeutics has received clearance from the US Food and Drug Administration (FDA) to initiate two phase 3 clinical studies with tabelecleucel (formerly known as ATA129) in patients with rituximab-refractory Epstein-Barr virus (EBV) associated post-transplant lymphoproliferative disorder (EBV+PTLD).
Contract Research & Services > Clinical Trials > News
Study shows experimental diabetes drug could enhance Alzheimer’s signs in mice
By PBR Staff Writer
A study conducted by the UK and Chinese researchers showed that an experimental diabetes drug may have improved the memory and brain function in mice with symptoms of Alzheimer’s disease.
Contract Research & Services > Clinical Trials > News
AbbVie's upadacitinib succeeds in phase 3 rheumatoid arthritis study
AbbVie says that its investigational oral JAK1-selective inhibitor upadacitinib (ABT-494) has demonstrated positive results as monotherapy in phase 3 rheumatoid arthritis study, meeting all primary and key secondary endpoints.
Contract Research & Services > Clinical Trials > News
Bristol-Myers makes equity investment in Taris Biomedical
By PBR Staff Writer
Bristol-Myers Squibb has made an equity investment in Taris Biomedical, a therapeutically urology company engaged in the development of treatments for patients suffering from difficult-to-treat bladder diseases.
Contract Research & Services > Clinical Trials > News
Pfizer, Array BioPharma to study different anti-cancer combinations
By PBR Staff Writer
Array BioPharma has established a clinical trial collaboration with Pfizer to study the safety and efficacy of various anti-cancer combinations.
Contract Research & Services > Clinical Trials > News
Regeneron and ISA Pharmaceuticals form immuno-oncology collaboration
Regeneron Pharmaceuticals and ISA Pharmaceuticals have formed a clinical collaboration to advance ISA101, an immunotherapy targeting human papillomavirus type 16 (HPV16)-induced cancer, in combination with cemiplimab (REGN2810), a PD-1 (programmed cell death protein 1) antibody.
Contract Research & Services > Clinical Trials > News
Allergan, Richter’s bipolar depression drug meets primary end point in phase 3 study
By PBR Staff Writer
Allergan and Gedeon Richter have announced that cariprazine met primary end point in a phase 3 study to treat bipolar I depression.
Contract Research & Services > Clinical Trials > News
Merck’s Keytruda fails to meet primary endpoint in gastric cancer trial
By PBR Staff Writer
Merck’s anti-PD-1 therapy Keytruda (pembrolizumab) has failed to meet primary endpoint in a phase 3 gastric cancer trial.
Contract Research & Services > Clinical Trials > News
Combination of AbbVie's venetoclax and Rituxan succeeds in phase 3 R/R CLL trial
By PBR Staff Writer
AbbVie and Roche’s Venclexta/Venclyxto (venetoclax) in combination with MabThera/Rituxan (rituximab) succeeded in a phase 3 trial in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) by meeting the primary endpoint.
Contract Research & Services > Clinical Trials > News
NIH to provide funding for Alzheimer's advance clinical trials
By PBR Staff Writer
US-based National Institutes of Health (NIH) is set to provide financial assistance to a new clinical trials consortium to enhance studies for therapies in Alzheimer’s disease and related dementias.
Contract Research & Services > Clinical Trials > News
Pfizer's breast cancer drug improves progression-free survival in Phase 3 trial
Pfizer announced that talazoparib has improved progression-free survival (PFS) in patients with germline (inherited) BRCA1/2-positive (gBRCA+) locally advanced or metastatic breast cancer (MBC) in the Phase 3 Embraca study.
Contract Research & Services > Clinical Trials > News
76-90 of 4306 results